NATALIA LAPTEVA to Treatment Outcome
This is a "connection" page, showing publications NATALIA LAPTEVA has written about Treatment Outcome.
Connection Strength
0.060
-
CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther. 2010 May; 10(5):725-33.
Score: 0.029
-
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 Jun; 5(6):880-894.
Score: 0.019
-
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 10; 19(10):1225-1232.
Score: 0.012